Key result
Saphenous vein progenitor cell injection enhances neovascularization and blood flow recovery in limb ischemia.
Why the study?
Non-bone marrow progenitor cells with proangiogenic capacities remain clinically unexploited due to scarcity, difficulty of access, and low ex vivo expansibility.
Population
Patients undergoing coronary artery bypass surgery
Comparison
CD34-positive/CD31-negative saphenous vein progenitor cells vs other cell types or conditions in vitro and in vivo
Design
Experimental study with cell isolation, culture, and intramuscular injection in immunodeficient mice
Follow-up
14 days after transplantation
Authors
Loading...
SVPs from discarded saphenous veins may provide an accessible autologous angiogenic source; leaves open clinical translation pending controlled human trials.
Saphenous vein-derived progenitor cells demonstrate proangiogenic potential and improve blood flow in ischemic models, suggesting a potential new therapeutic tool for angiogenic therapy.
Campagnolo et al. (2010) studied Patients undergoing coronary artery bypass surgery. Saphenous vein-derived progenitor cells (SVPs) was evaluated on Neovascularization and blood flow recovery. Intramuscular injection of saphenous vein-derived progenitor cells in ischemic limbs of immunodeficient mice improved neovascularization and blood flow recovery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: